What are the diagnostic steps for beta thalassemia?

Diagnosis of Beta Thalassemia

Diagnose beta thalassemia by identifying microcytic hypochromic anemia (MCV <80 fL) that fails to respond to iron supplementation, followed by hemoglobin electrophoresis showing elevated HbA2 (>3.5%) for beta thalassemia trait, or genetic testing to confirm specific mutations in the HBB gene. 1

Initial Hematologic Screening

Complete Blood Count Findings

• Mean corpuscular volume (MCV) is typically <80 fL with reduced mean corpuscular hemoglobin (MCH), creating a microcytic hypochromic pattern on blood smear 2, 1
• In beta thalassemia trait, MCV is markedly reduced to 60-70 fL and MCH to 19-23 pg, more severe than typically seen in iron deficiency 3
• Red blood cell count is normal or elevated despite the anemia, which helps distinguish thalassemia from iron deficiency 3

Critical Iron Status Assessment

• Always measure serum ferritin before attributing microcytic anemia solely to thalassemia trait, as concurrent iron deficiency can coexist and must be excluded 2, 1
• Normal or elevated ferritin levels in the presence of microcytic anemia strongly suggest thalassemia rather than iron deficiency 1

Definitive Diagnostic Testing

Hemoglobin Electrophoresis (First-Line for Beta Thalassemia Trait)

• HbA2 determination is the most decisive test for beta-thalassemia carrier detection, with levels >3.5% confirming beta thalassemia trait 3
• HbF (fetal hemoglobin) may be mildly elevated in some carriers 3
• This test distinguishes beta thalassemia trait from alpha thalassemia trait, where HbA2 is normal or low 3

Genetic Testing (Confirmatory and Essential for Severe Forms)

• Molecular analysis of the HBB gene on chromosome 11 confirms the diagnosis and identifies specific mutations (point mutations, small deletions, or insertions) 1
• Genetic testing is not required to confirm beta thalassemia trait diagnosis but is essential to predict disease severity and distinguish transfusion-dependent beta thalassemia major from non-transfusion-dependent forms 3
• DNA analysis enables accurate prenatal diagnosis on chorionic villi samples when both parents are carriers 3
• Accurate circular consensus long-read sequencing can detect rare thalassemia variants missed by conventional molecular analysis, identifying an additional 17.67% of clinically significant variants 4

Clinical Context That Triggers Diagnostic Evaluation

High-Risk Populations

• Prioritize screening in individuals of Mediterranean, Middle Eastern, Southeast Asian, and African ancestry, where beta thalassemia prevalence is highest due to historical malaria exposure 2, 1
• Failure to consider ethnicity leads to missed diagnoses 2, 1

Key Clinical Presentations by Age

• Infants are asymptomatic at birth because fetal hemoglobin does not require beta-globin chains 1
• Symptoms emerge at 1-2 years of age as fetal hemoglobin production declines and the switch to adult hemoglobin occurs 1
• Beta thalassemia major becomes life-threatening by age 1-2 years, requiring lifelong transfusions starting before age 2 1

Red Flag: Anemia Unresponsive to Iron

• The most clinically important diagnostic clue is persistent mild anemia that does NOT respond to iron supplementation despite compliance and absence of acute illness 2
• Iron deficiency anemia should show hemoglobin increase of 1 g/dL or hematocrit increase of 3% after 4 weeks of adequate iron therapy; failure to respond mandates further evaluation 2
• In pregnant women of appropriate ancestry with persistent mild anemia unresponsive to prenatal iron, immediately evaluate with MCV, RDW, and hemoglobin electrophoresis 2, 1

Diagnostic Algorithm Summary

1. Screen high-risk populations (Mediterranean, Middle Eastern, Southeast Asian, African ancestry) with CBC 2, 1
2. If MCV <80 fL with microcytic hypochromic anemia, measure serum ferritin 2, 1
3. If ferritin normal/elevated, proceed to hemoglobin electrophoresis 3
4. If HbA2 >3.5%, diagnose beta thalassemia trait 3
5. For severe anemia or family planning, perform genetic testing to identify specific HBB mutations and predict clinical severity 3
6. For prenatal diagnosis, perform DNA analysis on chorionic villi when both parents are carriers 3

Critical Pitfalls to Avoid

• Never prescribe iron supplementation to patients with confirmed beta thalassemia trait—it provides no benefit and may contribute to unnecessary iron accumulation 2, 1
• Do not rely on serum ferritin alone to assess cardiac iron burden in transfusion-dependent patients; it is an insufficient surrogate and requires cardiac MRI T2* for accurate assessment 5
• Do not use mathematical formulas (discriminant indices) as the sole basis for distinguishing thalassemia from iron deficiency; they have limited accuracy and must be confirmed with definitive testing 3